New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma

Annals of Oncology

Volumn 21, Issue 7, 2010, Pages 1560-1561

  Zucali, P A ^a   Giovannetti, E ^b   Assaraf, Y G ^c   Ceresoli, G L ^d   Peters, G J ^b   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Humanitas Gavazzeni Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; PEMETREXED; THYMIDYLATE SYNTHASE;

DRUG PROTEIN BINDING; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MALIGNANT MESOTHELIOMA; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARDIZATION;

EID: 77954282272     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq253     Document Type: Letter

References (5)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
2. Righi L, Capotti MG, Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28: 1534-1539.
3. Zucali P, Destro A, Ceresoli G et al. The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. In Presented at European Conference on Clinical Oncology (ECCO), 2009. Abstract ER-1513a.
4. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6: 404-417.
5. Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamatesynthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113: 4362-4369.